Sarah Fenton, M.D., PHD
Hematology & Oncology Physician in Chicago, Illinois.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,215 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Sarah Fenton, M.D., PHD reported a CMS MIPS final score of 94.1/100 - above the 83.1 national average - and filed 387 Medicare Part D claims in 2023.
- 94.1/100
- MIPS score · +11 vs avg
- 387
- Part D claims, 2023
- 80%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Sarah Fenton, M.D., PHD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
94 Top 25% higher than 75% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Sarah Fenton, M.D., PHD sits
This provider among hematology & oncology physician peers
Across the 4,233 hematology & oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Sarah Fenton, M.D., PHD writes more Part D claims than 29% of them and scores higher on MIPS quality than 73% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one hematology & oncology physician peer from a representative sample of 60; the gold marker is Sarah Fenton, M.D., PHD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Sarah Fenton, M.D., PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Sarah Fenton, M.D., PHD?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Illinois
How Hematology & Oncology Physician compares to other specialties among Illinois providers
Hematology & Oncology Physician ranks #66 among Illinois's specialties (0.2% of in-state providers)
Each bar is a specialty's share of the Illinois provider total, by primary NUCC taxonomy. The highlighted bar is Hematology & Oncology Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Sarah Fenton, M.D., PHD's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 94.1/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) - 94.1/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Hematology & Oncology Physician US NPIs
94.1/100 MIPS final score - 11.0 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Hematology & Oncology Physician. Quality dim: 82.6.
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Sarah Fenton, M.D., PHD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D., PHD credentials at 201 E HURON ST, Chicago, IL, 60611, with a listed phone of (312) 926-2253. NPI 1588027676 was issued on 04/05/2016.
Medicare Part D records for calendar year 2023 show 387 prescription claims written by this provider, covering 68 Medicare beneficiaries and totaling roughly $891K in drug spend, split 20% brand-name and 80% generic by claim count, with an opioid prescribing rate of 8.0%. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 94.1/100 for the 2023 performance year (Quality 82.6), compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1588027676 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D., PHD |
| Gender | Female |
| NPI Issued | 04/05/2016 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Sarah Fenton, M.D., PHD's current license status, disciplinary history, and board certifications with the Illinois Department of Financial and Professional Regulation in Illinois before relying on this page for a clinical or care decision.
How we sourced this profile
Profile fields combine the CMS NPPES monthly snapshot (provider directory, taxonomy, and address) with calendar-year 2023 Medicare Part D and MIPS public-use files when records are present. NPI 1588027676 is the unique 10-digit identifier CMS uses to link Fenton across every Medicare, Medicaid, and HIPAA-covered transaction. Read full methodology →
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Sarah Fenton, M.D., PHD. Source: openpaymentsdata.cms.gov.
Total received
$4.5K
Largest payer
PFIZER INC.
Most common payment type
Consulting Fee
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Illinois IDFPR 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~42K Illinois medical licensees in 2023 - they are NOT specific to Sarah Fenton, M.D., PHD. To verify Sarah Fenton, M.D., PHD's current license status, search the IDFPR public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
IDFPR publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Illinois disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
20% brand-name claims vs 80% generic, on 387 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 454
- Total Day Supply
- 12,195
- Brand vs Generic
- 20% brand / 80% generic
- Brand Drug Cost
- $631K
- Generic Drug Cost
- $260K
- Opioid Claims
- 31 (8.0% rate)
Patient Demographics
- Average Patient Age
- 76.5 years
- Avg HCC Risk Score
- 2.42
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Sarah Fenton, M.D., PHD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Prednisone
Prednisone
87 claims
- Abiraterone Acetate
Abiraterone Acetate
79 claims
- Nubeqa
Nubeqa
47 claims
- Orgovyx 26
Orgovyx
26 claims
- Hydrocodone-Acetam… 18
Hydrocodone-Acetaminophen
18 claims
- Gabapentin 17
Gabapentin
17 claims
- Dexamethasone 16
Dexamethasone
16 claims
- Bicalutamide 14
Bicalutamide
14 claims
| Drug | Claims |
|---|---|
| Prednisone | 87 |
| Abiraterone Acetate | 79 |
| Nubeqa Darolutamide | 47 |
| Orgovyx Relugolix | 26 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 18 |
| Gabapentin | 17 |
| Dexamethasone | 16 |
| Bicalutamide | 14 |
| Prochlorperazine Maleate | 12 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Sarah Fenton, M.D., PHD fits within the Hematology & Oncology Physician landscape nationally.
Sarah Fenton, M.D., PHD's 387 claims are below the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in Illinois
Other clinicians with the same primary specialty enrolled in Illinois, drawn from the same CMS NPPES roster as Fenton.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Illinois medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Illinois
Frequently Asked Questions
What is Sarah Fenton, M.D., PHD's specialty? ▼
How much does Sarah Fenton, M.D., PHD prescribe under Medicare Part D? ▼
What is Sarah Fenton, M.D., PHD's Medicare quality score? ▼
Where is Sarah Fenton, M.D., PHD located? ▼
What is Sarah Fenton, M.D., PHD's NPI number? ▼
Does Sarah Fenton, M.D., PHD prescribe more brand-name or generic drugs? ▼
Does Sarah Fenton, M.D., PHD prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does Sarah Fenton, M.D., PHD prescribe most often? ▼
Does Sarah Fenton, M.D., PHD accept Medicare? ▼
How can I verify Sarah Fenton, M.D., PHD's credentials? ▼
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology